INTERVIEWS

Dr. Paul Lammers, MD, MSc, President and Chief Executive Officer at Triumvira Immunologics discusses the company’s work in the development of novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with cancer.

Steve Glover, Co-Founder, Chairman, and CEO of ZyVersa Therapeutics, a clinical-stage specialty biopharmaceutical company discusses the work the company is doing to develop first-in-class drugs for patients with inflammatory or kidney diseases with high unmet medical needs. They are well positioned in the rapidly emerging inflammasome space with a highly differentiated inflammasome inhibitor (IC 100), and in kidney disease with a novel phase 2a-ready cholesterol efflux mediator (VAR 200). Lead products in each therapeutic area offer a “pipeline within a product,” with the potential for numerous indications. Currently, there is very little research being done in the renal space.

Meredith Manning, President of the Americas at PharmaEssentia, a global biotech, discusses the company’s work utilizing the power of interferons, a naturally occurring substance that helps the body’s immune system fight infection and diseases. PharmaEssentia has pioneered technology that leverages pegylation (or “extended release”) to administer interferons in a tolerable and effective way to treat certain myeloproliferative neoplasms (MPNs), including polycythemia vera (PV) at the source. This has opened the door to applying this therapy to other forms of rare blood cancers. Meredith discusses the importance of educating patients and physicians on early intervention to reduce the risk of disease progression. Meredith is passionate about solving the most pressing challenges in MPNs and is focused on cultivating relationships with community physicians to help more patients.

Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D., Executive Vice President & Chief Medical Officer, Head of Experimental Medicines at Genmab, an international biotechnology company, discusses the announcement from Genmab and Abbvie that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application for epcoritamab (DuoBody ®-CD3xCD20), an investigational subcutaneous bispecific antibody, for the treatment of patients with relapsed/refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy. The target action date for the FDA decision is May 21, 2023. For more information visit clinicaltrials.gov www.genmab.com

Mike Knox, father and author of the book “Vivien’s Rain: My Daughter’s Battle with Epilepsy” shares his journey with his daughter who was diagnosed with epilepsy when she was two and is now 16, and talks about Vivien’s success with VNS Therapy™. His recent efforts have been focused on passing a law for police and law enforcement in California to be trained on seizures and seizure first aid with the hope that his efforts will result in bringing peace of mind to families who are raising children with epilepsy and reducing the stigma associated with the condition. For more information about VNS Therapy™, visit VNSTherapy.com.

Returning guest, actor-producer, comic book author, and father, Greg Grunberg shares his personal journey as a caregiver and advocate to his own son, Jake who is living with epilepsy and he talks about how he is hosting an inspirational online video series called “The Care Giver” where he travels across the county helping tell stories of others in the epilepsy community…providing them strength knowing they’re not alone in their journey. For more information visit www.TheCareGiverSeries.com

Dr. Bob Dagher, MD, Chief Medical Officer at Enveric Biosciences, a biotechnology company dedicated to developing novel small-molecule therapeutics to transform the treatment of anxiety, depression, and addiction disorders discusses the company’s lead candidate, a next-generation, psilocybin analogue (psychedelics), that has been rationally designed to optimize delivery, offer dosing flexibility, and achieve therapeutic benefit at a low dose. Enveric has harnessed the world’s foremost library of psychedelic derivatives, The Psybrary™, a unique discovery, and development platform.

Andreas Raptopoulos, founder and CEO of Matternet, the first drone-centric healthcare delivery organization to secure Type Certification and a Production Certificate from the Federal Aviation Administration, discusses how he and his team are utilizing safety-focused and environmentally-sensitive best practices to actively transform deliveries conducted between hospitals, laboratories, pharmacies and other healthcare organizations. He talks about his long-term vision of making drone delivery an integral part of the healthcare system that will help people in a cost-effective way, reduce waste and have a positive impact on our environment. To learn more, visit Matternet’s website: https://mttr.net/.

Dr. George W. Sledge, Jr., newly appointed Executive Vice President and Chief Medical Officer of Caris Life Sciences, discusses why he made the move to Caris and the groundbreaking work he’ll be leading

Returning guest, Dr. Rick Baehner, MD, Chief Medical Officer of Precision Oncology at Exact Sciences discusses new data presented at the 2022 San Antonio Breast Cancer Symposium (SABCS) that strengthen the value of the Oncotype DX ® Breast Recurrence Score test as well as other data supporting their precision portfolio. He talks about Exact Science’s role in helping breast cancer patients make informed decisions about treatment and shares an update around a new test the company just launched that aids in therapy selection for advanced cancers.